The University of Alabama at Birmingham (UAB) has initiated the TRANSCEND-T2D-2 clinical trial to investigate a novel therapeutic approach for managing type 2 diabetes. This study seeks to evaluate the effectiveness of an investigational medicine in improving blood glucose control and promoting weight management in adults diagnosed with type 2 diabetes.
The clinical trial compares the investigational medicine against existing treatments for type 2 diabetes. Participants meeting specific criteria are being enrolled to determine if the new therapy offers superior glycemic control and weight reduction benefits.
Eligibility Criteria
To participate in the TRANSCEND-T2D-2 study, individuals must meet several inclusion criteria: they must be 18 years of age or older, have a confirmed diagnosis of type 2 diabetes, maintain a Body Mass Index (BMI) of 25 or greater, and exhibit Hemoglobin A1c (HbA1c) levels ranging from 7.0% to 10.5%. Furthermore, eligible participants must have been consistently taking a daily dosage of 1500mg or more of metformin for at least three months, with or without the concurrent use of an SGLT2 inhibitor (SGLT2i).
Study Objectives
The primary objective of the TRANSCEND-T2D-2 trial is to assess the investigational medicine's ability to improve blood glucose levels, as measured by HbA1c, and to facilitate weight management in individuals with type 2 diabetes. Researchers will compare these outcomes against those achieved with currently available treatments, providing insights into the potential advantages of the new therapy.
Contact Information
Individuals interested in learning more about the TRANSCEND-T2D-2 clinical trial or determining their eligibility can contact Tracie Thomas, RN, at 205-996-4015 or via email at tthoma@uab.edu.
